Research progress on the pathogenesis of immune checkpoint inhibitor-associated myocarditis
10.3760/cma.j.issn.0254-9026.2023.12.019
- VernacularTitle:免疫检查点抑制剂相关性心肌炎发病机制研究进展
- Author:
Zeyu WEN
1
;
Huili CAO
;
Yajing ZHAO
;
Chengmei YANG
;
Songshan LI
;
Huwei DAI
;
Kang ZENG
;
Bin YANG
Author Information
1. 山西医科大学，太原 030000
- Keywords:
Myocarditis;
Immunotherapy;
Immune checkpoint inhibitors
- From:
Chinese Journal of Geriatrics
2023;42(12):1489-1494
- CountryChina
- Language:Chinese
-
Abstract:
Immune checkpoint inhibitors(ICIs)have become the most widely used drugs in tumor immunotherapy, with ipilimumab and nivolumab as their representatives.However, the use of immune checkpoint inhibitors has brought about many immune-related adverse events, of which myocarditis is one of the most fatal adverse reactions.The pathogenesis of immune checkpoint inhibitor-associated myocarditis is not fully understood, mainly involving autoimmune T lymphocyte infiltration, regulatory T-cell dysfunction, cytokines, autoantibody production, genetic factors, the gut microbiome, etc.The treatment and management of immune checkpoint inhibitor-associated myocarditis require concerted efforts of multidisciplinary experts.
